BGB-11417
Sponsors
BeOne Medicines AG, University Of Cologne, Beigene Ltd., BeiGene, Tianjin Medical University Cancer Institute and Hospital
Conditions
Acute Myeloid LeukemiaChronic Lymphocytic Leukemia (CLL)LeukemiaLymphomaMCLMantle Cell LymphomaMature B-cell MalignanciesMyelodysplastic Syndromes
Phase 1
A Study of BGB-11417 in Participants With Myeloid Malignancies
RecruitingNCT04771130
Start: 2021-05-24End: 2028-02-08Target: 260Updated: 2026-03-04
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Active, not recruitingNCT04883957
Start: 2021-07-05End: 2026-04-30Updated: 2025-12-19
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Active, not recruitingNCT05471843
Start: 2022-09-05End: 2027-01-31Updated: 2025-09-09
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl 2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Active, not recruitingCTIS2022-500687-35-00
Start: 2023-04-04Target: 31Updated: 2025-10-27
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl‑2 Inhibitor BGB‑11417 in Patients With Myeloid Malignancies
RecruitingCTIS2023-508881-14-00
Start: 2022-03-21Target: 53Updated: 2025-10-31
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
RecruitingCTIS2023-507751-30-00
Start: 2024-05-27Target: 70Updated: 2025-10-10
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies
RecruitingCTIS2024-518829-15-00
Start: 2025-07-02Target: 14Updated: 2025-11-19
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell
Malignancies
RecruitingCTIS2024-516234-35-00
Start: 2025-10-15Target: 99Updated: 2026-01-14
Phase 2
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Active, not recruitingNCT05479994
Start: 2022-10-25End: 2027-08-25Updated: 2026-03-04
A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS TISLELIZUMAB (BGB-A317), A PD-1 INHIBITOR, WITH AND WITH-OUT SONROTOCLAX (BGB-11417), A BCL2 INHIBITOR, FOR TREATMENT OF PATIENTS WITH RICHTER TRANSFORMATION - CLL-RT1-Trial
RecruitingCTIS2023-504653-12-00
Start: 2020-02-10Target: 107Updated: 2025-12-15
An Open Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB 11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Active, not recruitingCTIS2023-503235-18-00
Start: 2024-01-31Target: 64Updated: 2025-11-17
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
RecruitingNCT06463691
Start: 2024-08-01End: 2029-07-31Target: 30Updated: 2025-05-11
A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruitingCTIS2024-513970-23-00
Start: 2025-02-27Target: 39Updated: 2025-12-10
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Not yet recruitingNCT07508995
Start: 2026-09-01End: 2033-07-01Target: 40Updated: 2026-04-03
Phase 3
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruitingCTIS2023-506948-17-00
Start: 2024-04-05Target: 206Updated: 2025-12-15
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
RecruitingCTIS2024-515593-27-00
Start: 2025-05-08Target: 140Updated: 2025-11-10
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingCTIS2024-517131-52-00
Start: 2025-11-03Target: 285Updated: 2025-12-02